<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and offers superior response and survival rates </plain></SENT>
<SENT sid="1" pm="."><plain>90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of beta irradiation </plain></SENT>
<SENT sid="2" pm="."><plain>Given in monotherapy, it constitutes an interesting alternative therapy for follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in second relapse </plain></SENT>
<SENT sid="3" pm="."><plain>Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> resistant to classical chemotherapy </plain></SENT>
</text></document>